Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings.[ Read More ]
The intrinsic value of one CODX stock under the base case scenario is HIDDEN Compared to the current market price of 1.06 USD, Co-Diagnostics, Inc. is HIDDEN
Current Assets | 62.1 M |
Cash & Short-Term Investments | 58.5 M |
Receivables | 331 K |
Other Current Assets | 3.26 M |
Non-Current Assets | 33.2 M |
Long-Term Investments | 773 K |
PP&E | 6 M |
Other Non-Current Assets | 26.4 M |
Current Liabilities | 5.75 M |
Accounts Payable | 1.48 M |
Short-Term Debt | 1.68 M |
Other Current Liabilities | 2.59 M |
Non-Current Liabilities | 3.56 M |
Long-Term Debt | 2.15 M |
Other Non-Current Liabilities | 1.41 M |
Revenue | 6.81 M |
Cost Of Revenue | 4.18 M |
Gross Profit | 2.63 M |
Operating Expenses | 44.1 M |
Operating Income | -42.7 M |
Other Expenses | -7.37 M |
Net Income | -35.3 M |
Net Income | -35.3 M |
Depreciation & Amortization | 1.23 M |
Capital Expenditures | -1.37 M |
Stock-Based Compensation | 8.34 M |
Change in Working Capital | 5.64 M |
Others | 1.38 M |
Free Cash Flow | -23.4 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
1 year ago
Mar 20, 2023
|
Bought 5.7 K USD
|
Brown Brian Lee
Chief Financial Officer |
+ 3000
|
1.899 USD |
3 years ago
Sep 08, 2021
|
Sell 20.9 K USD
|
Durenard Eugene
Director |
- 2000
|
10.455 USD |
3 years ago
May 19, 2021
|
Sell 93.2 K USD
|
BENSON REED L
General Counsel |
- 10920
|
8.5377 USD |
3 years ago
May 19, 2021
|
Sell 830 K USD
|
BENSON REED L
General Counsel |
- 97413
|
8.5244 USD |
3 years ago
May 19, 2021
|
Sell 8.53 USD
|
BENSON REED L
General Counsel |
- 1
|
8.53 USD |
3 years ago
Jan 15, 2021
|
Sell 419 K USD
|
Egan Dwight H
Chief Executive Officer |
- 38046
|
11 USD |
3 years ago
Jan 14, 2021
|
Sell 103 K USD
|
SERBIN RICHARD S
Director |
- 10000
|
10.29 USD |
3 years ago
Jan 13, 2021
|
Sell 106 K USD
|
Durenard Eugene
Director |
- 10500
|
10.09 USD |
3 years ago
Jan 13, 2021
|
Sell 121 K USD
|
NELSON JAMES B
Director |
- 11900
|
10.13 USD |
3 years ago
Jan 13, 2021
|
Sell 6.08 K USD
|
NELSON JAMES B
Director |
- 600
|
10.14 USD |
3 years ago
Dec 14, 2020
|
Sell 172 K USD
|
SERBIN RICHARD S
Director |
- 17000
|
10.1 USD |
3 years ago
Dec 10, 2020
|
Sell 102 K USD
|
Durenard Eugene
Director |
- 10000
|
10.15 USD |
3 years ago
Nov 25, 2020
|
Sell 940 K USD
|
BENSON REED L
CFO and Secretary |
- 89524
|
10.5 USD |
3 years ago
Nov 24, 2020
|
Sell 470 K USD
|
Egan Dwight H
Chief Executive Officer |
- 44764
|
10.51 USD |
3 years ago
Nov 23, 2020
|
Sell 747 K USD
|
Egan Dwight H
Chief Executive Officer |
- 71569
|
10.44 USD |
3 years ago
Nov 20, 2020
|
Sell 200 K USD
|
Egan Dwight H
Chief Executive Officer |
- 18017
|
11.09 USD |
4 years ago
May 20, 2020
|
Sell 451 K USD
|
Durenard Eugene
Director |
- 25000
|
18.03 USD |
4 years ago
May 26, 2020
|
Sell 456 K USD
|
Durenard Eugene
Director |
- 25000
|
18.24 USD |
4 years ago
May 20, 2020
|
Sell 460 K USD
|
Durenard Eugene
Director |
- 25000
|
18.4 USD |
4 years ago
May 26, 2020
|
Sell 457 K USD
|
Durenard Eugene
Director |
- 25000
|
18.26 USD |
4 years ago
May 19, 2020
|
Sell 462 K USD
|
SERBIN RICHARD S
Director |
- 25000
|
18.5 USD |
4 years ago
May 28, 2020
|
Sell 316 K USD
|
SERBIN RICHARD S
Director |
- 17500
|
18.03 USD |
4 years ago
May 28, 2020
|
Sell 135 K USD
|
SERBIN RICHARD S
Director |
- 7500
|
18 USD |
6 years ago
May 11, 2018
|
Bought 2.38 K USD
|
Satterfield Brent
Chief Science Officer |
+ 1305
|
1.82 USD |
6 years ago
May 03, 2018
|
Bought 955 USD
|
Satterfield Brent
Chief Science Officer |
+ 500
|
1.91 USD |
6 years ago
Apr 23, 2018
|
Bought 1.01 K USD
|
Satterfield Brent
Chief Science Officer |
+ 500
|
2.02 USD |
6 years ago
Apr 16, 2018
|
Bought 970 USD
|
Satterfield Brent
Chief Science Officer |
+ 500
|
1.94 USD |
6 years ago
Apr 09, 2018
|
Bought 4.92 K USD
|
Satterfield Brent
Chief Science Officer |
+ 2400
|
2.05 USD |
6 years ago
Apr 09, 2018
|
Bought 11.8 M USD
|
Satterfield Brent
Chief Science Officer |
+ 2400
|
4920 USD |